liver cirrhosis/triglyceride

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 35 rezilta yo

Alternation of Non-alcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risks After Liftestyle Modification: A Ultrasound Attenuation Imaging-Based Study

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background information Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the liver and is defined by evidence of hepatic steatosis (via imaging or histology) and is not due to secondary liver fat accumulation from excessive alcohol consumption or hereditary

Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This study is a prospective cross-sectional Multicenter National study, will include 1080 participants with BMI ≥ 24kg/m 2 with or without elevated liver enzymes. All will be subjected to; dietary history by already prepared food quality and quantity questionnaire, anthropometric data (BMI & waist

NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Objectives: To show that (i) expression of mRNA and proteins of the RANKL pathway (RANK, RANKL, OPG) in liver and (ii) serum concentration of RANKL/OPG proteins are correlated with the gravity of the NAFLD. Study protocol: Identify patients with different stages of NAFLD (mere steatosis, NASH, and

Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Obesity is associated with different chronic disorders such as metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and diabetes mellitus type 2 (DM2). It can be classified into mild, moderate and severe using different cut-off values of body mass index (BMI). Many interventions and

The Effect of Curcumin on Liver Fat Content in Obese Subjects

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The prevalence of obesity is increasing worldwide. Obesity and its associated complications represent an enormous burden for obese individuals, their families, healthcare systems and societies. Non-alcoholic fatty liver disease (NAFLD) has emerged as a frequent and serious complication of obesity.

Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The hepatitis C virus (HCV) is an enveloped, single-stranded positive-sense Ribo-Nucleic Acid virus which is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC), and infects approximately 3 % of the world population(150-170 million). One of the countries

De Novo Lipogenesis in Severity of NAFLD

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The development of nonalcoholic fatty liver disease (NAFLD) progresses from a state of elevated intrahepatic triglycerides (IHTG) to liver inflammation, and ultimately, hepatic apoptosis and fibrosis. NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Nonalcoholic fatty liver disease (NAFLD) is a public health problem in patients with type 2 diabetes mellitus (T2DM). The presence of type 2 diabetes in patients with NAFLD is a risk factor for its progression to a more severe liver disease known as nonalcoholic steatohepatitis (NASH).

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The study is a two-arm (placebo, lanifibranor 800 mg/day), randomized (1:1), double-blind, placebo-controlled, 24-week treatment study. Sixty four patients with T2DM will be randomized, allowing for a 10% drop-out rate. The diagnosis of NAFLD on imaging will be done by measuring IHTG using the

ObeSity Related Colorectal Adenoma Risk

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Bowel cancer, or colorectal cancer (CRC), is the second most common cancer affecting both men and women in England. The majority of CRCs develop from a pre-cancerous type of growth in the bowel called an adenoma. Detecting and removing these adenomas is important in reducing CRC risk. A study which

Lifestyle Intervention in Fatty Liver (NAFLD)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background Non-Alcoholic Fatty Liver Disease (NAFLD), including its more pathologic consequence, non-alcoholic steatohepatitis (NASH), is believed to be the most common chronic liver disease worldwide, affecting between 6 to 37% of the population. NAFLD is a so called 'silent killer', as clinical

Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Exocrine pancreatic insufficiency (EPI) is defined as the inability of the pancreas to perform a normal digestive function. Habitually, it occurs as a result of a severe reduction in the secretion of pancreatic enzymes, although - less frequently - it may be due to the inability of these enzymes to

Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This prospective study have been approved by Taipei Medical University-Joint Institutional Review Board. The starting point for each patient is the day of surgery and the end-point is 1 year after the operation. During bariatric surgery, all patients would undergo a liver biopsy under laparoscopic

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye